Jerusalem, Israel, February 15, 2001
Teva Concludes Strategic Agreements with Aventis to Acquire TMP, and with Lundbeck to Extend the Existing Cooperation to Oral CopaxoneŽ
Jerusalem, Israel, February 14, 2001
Teva Announces Fourth Quarter Earnings Conference Call
Jerusalem, Israel, February 11, 2001
Teva Announces Final Approvals of Nifedipine XL 30mg and Etodolac ER 400mg
Jerusalem, Israel, February 7, 2001
Teva Reaffirms Confidence in Sales of Sustained Release Generic Products
Jerusalem, Israel, January 2, 2001
Israel Makov Appointed COO
Jerusalem, December 29, 2000
Teva Launches CopaxoneŽ in the U.K.
Jerusalem, Israel, December 5, 2000
Teva Received Final Approval for Nifedipine CC 60mg and will Launch Immediately
Jerusalem, Israel, December 5, 2000
Teva Earnings Per Share for Q3 2000 Rise 26% Copaxone Sales Rise 59%
Jerusalem, Israel, November 7, 2000
Teva Received Final Approval for Doxazosin Mesylate
Jerusalem, Israel, October 22, 2000
Teva Announces Pricing of Convertible Debenture Offering
Jerusalem, Israel, October 12, 2000
Teva Announces Final Approval of Nifedipine XL 60 mg and will Launched Imminently
Jerusalem, Israel, September 28, 2000
Teva Announces Proposed Offering of Convertible Debentures in a Rule 144a Offering
Jerusalem, Israel, September 22, 2000
Teva Receives First Generic Approval for Amoxicillin 500 and 875 mg Tablets
Jerusalem, Israel, September 19, 2000
the Israeli Supreme Court Fully Acquitted Eli Hurvitz, Teva's President and CEO
JERUSALEM, Israel, September 7, 2000
Teva Received Two Approvals:Final Approval for Enalapril to be Shipped Immediately Tentative Approval for Loratadine
Jerusalem, Israel, August 23, 2000
Teva Received Marketing Approval for CopaxoneŽ in the U.K.
JERUSALEM, Israel, August 13, 2000
Teva to Receive 180 Days Market Exclusivity for Etodolac ER 500 & 600mg and will Ship Immediately
Jerusalem, Israel, August 1, 2000
Teva Pharmaceutical Industries, Ltd. and Aventis Pharmaceuticals Announce 2Q 2000 Record Sales of CopaxoneŽ
Jerusalem, Israel and Parsippany, N.J., July 31, 2000
Teva Pharmaceutical Industries Ltd. Reports Second Quarter Earnings Per Adr Up 32%
Jerusalem, Israel,, July 31, 2000
Teva Pharmaceutical Industries Ltd Announces tentative FDA Approval of Nifedipine XL, 30 mg and 60 mg
Jerusalem, Israel, July 25, 2000
Teva Pharmaceutical Industries Ltd. US$ 135 Million Multicurrency Term Loan Facility 2000-2005
Jerusalem, Israel, July 17, 2000
Teva Pharmaceutical Industries Ltd Receives Final FDA Approval of Nabumetone 750mg 180 Days Market Exclusivity Under Paragraph IV
Jerusalem, Israel, June 7, 2000
Teva Pharmaceutical Industries Ltd. Announces CopaxoneŽ Recommended for Approval in the U.K. a Major Step Towards the Approval in the E.U.
Jerusalem, Israel, June 2, 2000
Teva Pharmaceutical Industries Ltd Receives Final FDA Approval of Tamoxifen Citrate 10 mg
Jerusalem, Israel, June 1, 2000
Teva Pharmaceutical Industries Ltd Receives Final FDA Approval of Nabumetone 500 mg 180 Days Market Exclusivity Under Paragraph IV
Jerusalem, Israel, May 31, 2000
Teva Pharmaceutical Industries Ltd. Reports First Quarter 2000 Financial Results; First Quarter Earnings Per ADR Up 30%
Jerusalem, Israel, May 4, 2000
Teva Pharmaceutical Receives First FDA Approval of Ketoconazole 2% Cream
Jerusalem, Israel, April 26, 2000
Teva & Lundbeck Announce the Successful Completion of a Phase III Trial for a New Treatment for Parkinson's Patients
JERUSALEM, Israel, April 7, 2000
Teva Announces Completion of Novopharm Acquisition
Jerusalem, Israel, April 5, 2000
Teva Pharmaceutical Industries Ltd. to Market BTG's Human Growth Hormone in the United States
Jerusalem, Israel, March 30, 2000
Teva Pharmaceutical Industries Ltd. to Launch Generic Equivalent of Voltaren XR Immediately
Jerusalem, Israel, February 22, 2000
Teva Pharmaceutical Industries Ltd. Declares Regular Quarterly Cash Dividend and Announces a Two for One Stock Split
Jerusalem, Israel, February 14, 2000
Teva Pharmaceutical Industries Ltd. Reports 1999 Fourth Quarter and Year End Financial Results;
Jerusalem, Israel, February 14, 2000
Teva Pharmaceutical Industries Ltd. Signs Definitive Agreement to Acquire Novopharm Ltd.
Jerusalem, Israel, February 1, 2000
Archive: 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999
| Legal Note | Site Map | Copyright © 1999 - 2008 Teva. All rights reserved |